MEDI-528, now recognized as enokiizumab , represents a innovative therapeutic targeting the insulin-like growth factor 1 receptor , a crucial protein implicated in various epidermal ailments. Early clinical https://berthaqdwl593927.wikiexpression.com/6527744/enokizumab_a_deep_dive_into_medi_528_and_its_potential